CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.870
-0.010 (-0.20%)
At close: Mar 12, 2026, 4:00 PM EDT
4.890
+0.020 (0.41%)
After-hours: Mar 12, 2026, 7:16 PM EDT
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $5.96M in the quarter ending September 30, 2025, a decrease of -82.16%. This brings the company's revenue in the last twelve months to $113.63M, down -10.26% year-over-year. In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth.
Revenue (ttm)
$113.63M
Revenue Growth
-10.26%
P/S Ratio
7.26
Revenue / Employee
$939,099
Employees
121
Market Cap
825.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Arvinas | 262.60M |
| Phathom Pharmaceuticals | 175.11M |
| ARS Pharmaceuticals | 84.28M |
| Kura Oncology | 67.48M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
CTMX News
- 8 days ago - CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics to Present at Upcoming February Conferences - GlobeNewsWire
- 6 weeks ago - Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - GlobeNewsWire
- 7 weeks ago - Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics - Business Wire
- 2 months ago - CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - CytomX Therapeutics Announces Business Update and Company Milestones for 2026 - GlobeNewsWire
- 3 months ago - CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling - Seeking Alpha
- 3 months ago - CytomX Therapeutics to Present at Upcoming December Investor Conferences - GlobeNewsWire